Abdominal Aortic Aneurysm Market

DelveInsight’s ‘Abdominal Aortic Aneurysm (AAA)- Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the Abdominal Aortic Aneurysm (AAA) historical and forecasted epidemiology as well as the Abdominal Aortic Aneurysm (AAA) market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

 

The Abdominal Aortic Aneurysm (AAA) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Abdominal Aortic Aneurysm (AAA) market size. The Report also covers current Abdominal Aortic Aneurysm (AAA) treatment practice, market drivers, market barriers, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Abdominal Aortic Aneurysm (AAA) Disease Understanding and Treatment 

Abdominal Aortic Aneurysm (AAA) Overview

Aneurysms that occur in the section of the aorta that runs through the abdomen (abdominal aorta) are called abdominal aortic aneurysms (AAA). The portion of the aorta that lies deep inside the abdomen, right in front of the spine, is called the abdominal aorta. Over time, artery walls may become weak and widen. The pressure of blood pumping through the aorta may then cause this weak area to bulge outward, like a balloon (called an aneurysm). An AAA occurs when this type of vessel weakening happens in the portion of the aorta that runs through the abdomen. The majority of AAAs result from atherosclerosis, a chronic degenerative disease of the artery wall, in which fat, cholesterol, and other substances build up in the walls of arteries and form soft or hard deposits called plaques. AAA typically develop slowly over a period of many years and hardly ever cause any noticeable symptoms. Occasionally, especially in thin patients, a pulsating sensation in the abdomen may be felt. The larger an aneurysm grows, the greater the chance it will burst or rupture.

 

People who have this type of aneurysm do not notice it usually, and this is because it typically does not cause any symptoms. AAA may be detected incidentally or at the time of rupture. An arterial aneurysm is defined as a permanent localized dilatation of the vessel at least 150% compared to a relative normal adjacent diameter of that artery

 

Abdominal Aortic Aneurysm (AAA) Diagnosis 

Many AAAs are accidentally found on ultrasound examinations, x-rays or CT scans, and the patient is often being examined for an unrelated reason. In other patients who experience symptoms and seek medical attention, a physician may be able to feel a pulsating aorta or hear abnormal sounds in the abdomen with the stethoscope. A physical examination can usually initiate the diagnosis of AAA. The health care professional may be able to feel a pulsatile mass in the center of the abdomen and make the clinical diagnosis. In obese patients with a large girth, a physical exam is less helpful. In very thin patients, the aorta can often be seen to pulsate under the skin, and this may be a normal finding. Listening with a stethoscope may also reveal a bruit or abnormal sound from the turbulence of blood within the aneurysm.

Continued in the report…..

 

Abdominal Aortic Aneurysm (AAA) Treatment 

Currently, there is no drug therapy to limit the progression of AAA. As an aneurysm grows in size, the aorta wall becomes weaker and weaker, which means surgical intervention may be needed. The goal of any treatment strategy is to prevent the rupture of an aneurysm by controlling its growth. If a large AAA is detected before it ruptures, most people will be advised to have treatment to prevent it from rupturing. 

 

If the aneurysm is less than 5 cm or 2 inches, the doctor might try to treat it with medication first. They might prescribe drugs, such as beta-blockers and calcium channel blockers, to lower the blood pressure and relax the blood vessels. These medications will lessen the chance of rupture of aneurysm. Indeed, several therapeutic effects of pharmacological agents have been reported in experimental models, and some agents have undergone clinical trials. Treatment with statins, angiotensin-converting enzyme inhibitors, antibiotics, and anti-inflammatory agents appears to inhibit the growth rate of AAA in humans. 

Continued in the report…..

Abdominal Aortic Aneurysm (AAA) Epidemiology   

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Population of AAA, Total Gender-specific Diagnosed Prevalent Cases of AAA, Size-specific Diagnosed Prevalent Cases of AAA, and Treatable Population of AAA scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

 

Key Findings

  • Total Diagnosed prevalent population of Abdominal Aortic Aneurysm (AAA) in 7MM was estimated to be 1,641,380 cases in 2021 and is expected to increase in during the study period [2019–2032].  
  • Total Diagnosed prevalent cases of AAA in the US was estimated to be 752,408 in 2021 which is the highest among all the 7MM countries
  • The US accounted for the highest prevalent population of AAA among 7MM with 8,773 cases in 2021.
  • Among the European five countries the total prevalent population of Abdominal Aortic Aneurysm (AAA) is highest in Germany (192,532), followed by the France (138,193), Italy (68,202) had the lowest prevalent cases among the EU-5 countries.
  • Total prevalent population of Abdominal Aortic Aneurysm (AAA) in Japan was estimated to be 253,883 cases in 2021 and is expected to decrease in during the forecast period [2022–2032].
  • In the US, the highest number of cases were found to be having Small AAA (3 cm to 4.4 cm across) (696,730 cases) in 2021. Large AAA (5.5 cm or more across) were found in the least number of cases, i.e. 3,010 cases in 2021. Around 60,193 cases had Medium AAA (4.5 cm to 5.4 cm across) 2021. These cases are expected to increase in the forecast period. 

Country-Wise Abdominal Aortic Aneurysm (AAA) Epidemiology 

The epidemiology segment also provides the Abdominal Aortic Aneurysm (AAA) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

Abdominal Aortic Aneurysm (AAA) Device Chapters

Abdominal Aortic Aneurysm (AAA) Marketed Devices

 

AFX® Endovascular AAA System: Endologix LLC

The AFX® Endovascular AAA System is an endovascular graft system intended to treat patients with AAA. The device has a unique design in which the metal frame is on the inside of the fabric. It integrates anatomical fixation with an advanced delivery system and graft material technology. AFX® uses a low profile, precise delivery system and proprietary stent graft material (DuraPly™ ePTFE Graft Material) and provides reliable and durable AAA repair. The AFX®2 bifurcated endograft system provides confident control for improved accessibility every step of the way.

Products detail in the report…

 

Abdominal Aortic Aneurysm (AAA) Emerging Devices 

 

AAA Stent Graft System: Lifetech Scientific

The company’s AAA Stent Graft System is indicated to treat patients with an infrarenal AAAs. On September 30, 2018, Lifetech Scientific initiated its trial to evaluate the safety and efficacy of the AAA Stent Graft System for the infrarenal AAAs.

Products detail in the report…

 

Fenestrated Altura FEVAR Stent Graft: Lombard Medical

Endovascular treatment of aortic diseases has improved in recent years. Fenestrated Endovascular Aortic Aneurysm Repair (FEVAR) is an almost new minimally invasive technique for repairing thoracoabdominal or complex AAAs.

Products detail in the report…

List to be continued in the report…

Abdominal Aortic Aneurysm Market Outlook

Key Findings

  • The market size of AAA in the 7MM is estimated to be USD 1,579.9 million in 2021, which is further expected to increase by 2032.
  • The United States holds the largest market share of the AAA among the 7MM countries. In 2021, the market size of AAA in the US was USD 1,065.7 million.
  • In 2021, among the EU-5 countries, Germany had the highest market share, followed by France and the UK.
  • Japan holds the smallest share of the 7MM AAA market with a market size of USD 137.8 million in 2021 that is expected to increase by 2032.

 

The United States Market Outlook

This section provides the total Abdominal Aortic Aneurysm (AAA)market size and market size by therapies in the United States.

 

EU-5 Market Outlook

The total Abdominal Aortic Aneurysm (AAA)market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan Market Outlook 

The total Abdominal Aortic Aneurysm (AAA)market size and market size by therapies in Japan are provided.

Abdominal Aortic Aneurysm (AAA) Development Activities 

The report provides insights into different therapeutic candidates in phase II and phase III stage. It also analyzes key players involved in developing targeted therapeutics. 

Reimbursement Scenario in Abdominal Aortic Aneurysm (AAA)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy. 

Competitive Intelligence Analysis 

We perform competitive market Intelligence analysis of the Abdominal Aortic Aneurysm (AAA) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. 

Scope of the Report

  • The report covers the descriptive overview of Abdominal Aortic Aneurysm (AAA), explaining its causes, symptoms, pathophysiology, genetic basis, diagnosis, and currently available therapies.
  • Comprehensive insight has been provided into the Abdominal Aortic Aneurysm (AAA) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Abdominal Aortic Aneurysm (AAA) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Abdominal Aortic Aneurysm (AAA) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Abdominal Aortic Aneurysm (AAA) market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA, increasing prevalence, and effectiveness of drugs will positively drive the Abdominal Aortic Aneurysm (AAA) market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Abdominal Aortic Aneurysm (AAA) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Abdominal Aortic Aneurysm (AAA). The launch of emerging therapies will significantly impact the Abdominal Aortic Aneurysm (AAA)market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Abdominal Aortic Aneurysm (AAA) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Abdominal Aortic Aneurysm (AAA) Pipeline Analysis
  • Abdominal Aortic Aneurysm (AAA) Market Size and Trends
  • Market Opportunities

Abdominal Aortic Aneurysm (AAA) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage 
  • Abdominal Aortic Aneurysm (AAA) Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market

Abdominal Aortic Aneurysm (AAA) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the Abdominal Aortic Aneurysm (AAA) market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Abdominal Aortic Aneurysm (AAA) total market size as well as market size by therapies across the 7MM during the forecast period (2022–2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Abdominal Aortic Aneurysm (AAA)market size during the forecast period (2022–2032)?
  • At what CAGR, the Abdominal Aortic Aneurysm (AAA) market is expected to grow at the 7MM level during the forecast period (2022–2032)?
  • What would be the Abdominal Aortic Aneurysm (AAA) market outlook across the 7MM during the forecast period (2022–2032)?
  • What would be the Abdominal Aortic Aneurysm (AAA) market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burdens, and unmet needs of Abdominal Aortic Aneurysm (AAA)?
  • What is the historical Abdominal Aortic Aneurysm (AAA) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Abdominal Aortic Aneurysm (AAA) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Abdominal Aortic Aneurysm (AAA)?
  • Out of the above-mentioned countries, which country would have the highest population of Abdominal Aortic Aneurysm (AAA) during the forecast period (2022–2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Abdominal Aortic Aneurysm (AAA)along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Abdominal Aortic Aneurysm (AAA)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Abdominal Aortic Aneurysm (AAA) therapies? 
  • What are the 7MM historical and forecasted market of Abdominal Aortic Aneurysm (AAA)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving Abdominal Aortic Aneurysm (AAA).
  • To understand the future market competition in the Abdominal Aortic Aneurysm (AAA) market and an insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Abdominal Aortic Aneurysm (AAA) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Abdominal Aortic Aneurysm (AAA) market.
  • To understand the future market competition in the Abdominal Aortic Aneurysm (AAA) market.

1. Key Insights

2. Report Introduction

3. AAA Pharma Market Overview at a Glance

3.1. Pharmacological Market Share (%) Distribution of AAA in 2019

3.2. Pharmacological Market Share (%) Distribution of AAA in 2032

4. Disease Background and Overview

4.1. Introduction

4.2. Abdominal Aortic Aneurysm (AAA)

4.3. Symptoms of Abdominal Aortic Aneurysm

4.4. Causes or risk factors of Abdominal Aortic Aneurysm

4.5. Complications of Abdominal Aortic Aneurysm

4.5.1. Rupture

4.5.2. Contained Rupture

4.5.3. Infected (Mycotic) Aneurysms

4.5.4. Aorto-enteric Fistulas

4.5.5. Aorto-caval fistulas

4.6. Pathophysiology of Abdominal Aortic Aneurysm

4.7. Role for Epigenetics in Abdominal Aortic Aneurysm Pathogenesis

4.8. Diagnosis of Abdominal Aortic Aneurysm

4.9. Screening for Abdominal Aortic Aneurysm

5. Treatment

5.1. Pharmacological therapy for AAA

5.1.1. Statins

5.1.2. Angiotensin-converting enzyme-inhibitors and Ang II receptor blockers

5.1.3. Antibiotic agents

5.1.4. Anti-inflammatory agents

5.2. Non-pharmacological therapies

5.2.1. Surgery

6. Abdominal Aortic Aneurysm (AAA): Regulatory Framework

6.1. United States Regulation of AAA Devices

6.2. European Regulation of AAA Devices

6.3. Japan Regulation of AAA Devices

7. Abdominal Aortic Aneurysm (AAA): Reimbursement Scenario

7.1. Reimbursement Scenario in the United States

7.2. Reimbursement Scenario in Europe

7.3. Reimbursement Scenario in Japan

8. Abdominal Aortic Aneurysms: Marketed Products

8.1. Competitive Assessment

8.2. Endologix LLC

8.2.1. Company Overview

8.2.2. Product Portfolio

8.3. Cardinal Health

8.3.1. Company Overview

8.3.2. Financial Health

8.3.3. Product Portfolio

8.4. Cook Medical

8.4.1. Company Overview

8.4.2. Product Portfolio

8.5. W. L. Gore & Associates, Inc.

8.5.1. Company Overview

8.5.2. Product Portfolio

8.6. Terumo Aortic

8.6.1. Company Overview

8.6.2. Product Portfolio

8.7. Medtronic

8.7.1. Company Overview

8.7.2. Financial Health

8.7.3. Product Portfolio

8.8. MicroPort Scientific Corporation

8.8.1. Company Overview

8.8.2. Financial Health

8.8.3. Product Portfolio

8.9. Braile Biomédica

8.9.1. Company Overview

8.9.2. Product Portfolio

8.10. Artivion, Inc.

8.10.1. Company Overview

8.10.2. Financial Health

8.10.3. Product Portfolio

8.11. Lifetech Scientific

8.11.1. Company Overview

8.11.2. Financial Health

8.11.3. Product Portfolio

8.12. Lombard Medical

8.12.1. Company Overview

8.12.2. Product Portfolio

9. Abdominal Aortic Aneurysm: Emerging Devices

9.1. Competitive Assessment

9.2. Abdominal Aortic Aneurysm Stent Graft System: Lifetech Scientific (Shenzhen) Co., Ltd.

9.2.1. Company Overview

9.2.2. Product Portfolio

9.3. Lombard Medical

9.3.1. Company Overview

9.3.2. Product Portfolio

9.4. Endologix LLC

9.4.1. Company Overview

9.4.2. Product Portfolio

9.5. Latecba SA

9.5.1. Company Overview

9.5.2. Product Portfolio

9.6. Nectero Medical

9.6.1. Company Overview

9.6.2. Product Portfolio

9.7. Cardiatis, SA

9.7.1. Company Overview

9.7.2. Product Portfolio

9.8. Hangzhou Endonom Medtech Co., Ltd.

9.8.1. Company Overview

9.8.2. Product Portfolio

10. AAA Epidemiology and Patient Population Analysis- 7MM

10.1. Key Findings

10.2. 7MM Total Diagnosed Prevalent Population of AAA

10.3. 7MM Total Gender-Specific Prevalent Population of AAA

10.4. 7MM Total Size-specific prevalence of AAA

10.5. 7MM Total Treatable Population of AAA

10.6. 7MM Total Treatable Population by Type of Treatment of AAA

10.7. Assumptions and Rationale for Epidemiology Analysis

10.8. The United States

10.8.1. Total Diagnosed Prevalent Population of AAA in the United States

10.8.2. Total Gender-specific Prevalent Cases of AAA in the United States

10.8.3. Total Size-Specific Prevalence of AAA in the United States

10.8.4. Total Treatable Population of AAA in the United States

10.8.5. Total Treatable Population by Type of Treatment of AAA in United States

10.9. EU5

10.9.1. Germany

10.9.2. France

10.9.3. Italy

10.9.4. Spain

10.9.5. The United Kingdom

10.10. Japan

10.10.1. Total Diagnosed Prevalent Population of AAA in the Japan

10.10.2. Total Gender-specific Prevalent Cases of AAA in the Japan

10.10.3. Total Size-Specific Prevalence of AAA in the Japan

10.10.4. Total Treatable Population of AAA in the Japan

10.10.5. Total Treatable Population by Type of Treatment of AAA in Japan

11. AAA Pharma Market Analysis-7MM

11.1. Key Findings

11.2. 7MM Total Market Size of AAA Pharma

11.3. 7MM Total Market Size of AAA by Pharmacological Therapies

11.4. Assumptions and Rationale of Market Analysis

11.5. United States Market Size

11.5.1. United States total Market Size of AAA

11.5.2. United States Total Market Size of AAA by Pharmacological Therapies

11.6. Germany Market Size

11.6.1. Germany total Market Size of AAA

11.6.2. Germany Total Market Size of AAA by Pharmacological Therapies

11.7. France Market Size

11.7.1. France total Market Size of AAA

11.7.2. France Total Market Size of AAA by Pharmacological Therapies

11.8. Spain Market Size

11.8.1. Spain total Market Size of AAA

11.8.2. Spain Total Market Size of AAA by Pharmacological Therapies

11.9. Italy Market Size

11.9.1. Italy total Market Size of AAA

11.9.2. Italy Total Market Size of AAA by Pharmacological Therapies

11.10. United Kingdom Market Size

11.10.1. United Kingdom total Market Size of AAA

11.10.2. United Kingdom Total Market Size of AAA by Pharmacological Therapies

11.11. Japan Market Size

11.11.1. Japan total Market Size of AAA

11.11.2. Japan Total Market Size of AAA by Pharmacological Therapies

12. Unmet Needs

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Appendix

16.1. Report Methodology

16.2. Bibliography

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

List of Table

Table 1: Summary of AAA Epidemiology and Market (2019–2032)

Table 2: Abdominal aortic aneurysm endovascular devices commonly used in the United States

Table 3: Assessment based on the stage

Table 4: Company Profile: Endologix LLC

Table 5: Company Profile: Cardinal Health

Table 6: Company Profile: Cook Medical

Table 7: Company Profile: W. L. Gore & Associates, Inc.

Table 8: Company Profile: Terumo Aortic

Table 9: Company Profile: Medtronic

Table 10: Company Profile: MicroPort Scientific Corporation

Table 11: Company Profile: Braile Biomédica

Table 12: Company Profile: Artivion, Inc.

Table 13: Company Profile: Lifetech Scientific

Table 14: Company Profile: Lombard Medical

Table 15: Emerging Abdominal Aortic Aneurysm Devices

Table 16: Company Profile: Lifetech Scientific (Shenzhen) Co., Ltd.

Table 17: Company Profile: Lombard Medical

Table 18: Company Profile: Endologix LLC

Table 19: Company Profile: Latecba SA

Table 20: Company Profile: Nectero Medical

Table 21: Company Profile: CARDIATIS, SA

Table 22: company Profile: Hangzhou Endonom Medtech Co., Ltd.

Table 23: Total Prevalent Patient Population of AAA in 7MM (2019–2032)

Table 24: Total Gender-specific Prevalent Population of AAA (2019–2032)

Table 25: Total Size-Specific Prevalence of AAA (2019–2032)

Table 26: Total Treatable Population of AAA (2019–2032)

Table 27: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Table 28: Total Diagnosed Prevalence of AAA (2019–2032)

Table 29: Total Diagnosed Gender-Specific Prevalence of AAA (2019–2032)

Table 30: Size-Specific Prevalence of AAA (2019–2032)

Table 31: Total Treatable Population of AAA (2019–2032)

Table 32: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Table 33: Total Diagnosed Prevalence of AAA (2019–2032)

Table 34: Total Diagnosed Gender-Specific Prevalence of AAA (2019–2032)

Table 35: Gender-specific Prevalence of AAA (2019–2032)

Table 36: Total Treatable Population of AAA (2019–2032)

Table 37: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Table 38: Total Diagnosed Prevalence of AAA (2019–2032)

Table 39: Total Diagnosed Gender-Specific Prevalence of AAA (2019–2032)

Table 40: Gender-specific Prevalence of AAA (2019–2032)

Table 41: Total Treatable Population of AAA (2019–2032)

Table 42: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Table 43: Total Diagnosed Prevalence of AAA (2019–2032)

Table 44: Total Diagnosed Gender-Specific Prevalence of AAA (2019–2032)

Table 45: Gender-specific Prevalence of AAA (2019–2032)

Table 46: Total Treatable Population of AAA (2019–2032)

Table 47: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Table 48: Total Diagnosed Prevalence of AAA (2019–2032)

Table 49: Total Diagnosed Gender-Specific Prevalence of AAA (2019–2032)

Table 50: Gender-specific Prevalence of AAA (2019–2032)

Table 51: Total Treatable Population of AAA (2019–2032)

Table 52: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Table 53: Total Diagnosed Prevalence of AAA (2019–2032)

Table 54: Total Diagnosed Gender-Specific Prevalence of AAA (2019–2032)

Table 55: Gender-specific Prevalence of AAA (2019–2032)

Table 56: Total Treatable Population of AAA (2019–2032)

Table 57: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Table 58: Total Diagnosed Prevalence of AAA (2019–2032)

Table 59: Total Diagnosed Gender-Specific Prevalence of AAA (2019–2032)

Table 60: Gender-specific Prevalence of AAA (2019–2032)

Table 61: Total Treatable Population of AAA (2019–2032)

Table 62: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Table 63: Total Market Size for AAA in 7MM in USD million (2019-2032)

Table 64: Total Market Size for AAA by Pharmacological Therapies in 7MM in USD million (2019-2032)

Table 65: Total Market Size for AAA in United States in USD million (2019-2032)

Table 66: Total Market Size for AAA by Pharmacological Therapies in the United States in USD million (2019-2032)

Table 67: Total Market Size for AAA in Germany in USD million (2019-2032)

Table 68: Total Market Size for AAA by Pharmacological Therapies in Germany in USD million (2019-2032)

Table 69: Total Market Size for AAA by Pharmacological Therapies in France in USD million (2019-2032)

Table 70: Total Market Size for AAA by Pharmacological Therapies in France in USD million (2019-2032)

Table 71: Total Market Size for AAA in Spain in USD million (2019-2032)

Table 72: Total Market Size for AAA by Pharmacological Therapies in Spain in USD million (2019-2032)

Table 73: Total Market Size for AAA in Italy in USD million (2019-2032)

Table 74: Total Market Size for AAA by Pharmacological Therapies in Italy in USD million (2019-2032)

Table 75: Total Market Size for AAA in United Kingdom in USD million (2019-2032)

Table 76: Total Market Size for AAA in United Kingdom in USD million (2019-2032)

Table 77: Total Market Size for AAA in Japan in USD million (2019-2032)

Table 78: Total Market Size for AAA by Pharmacological Therapies in Japan in USD million (2019-2032)

List of Figures

Figure 1: Aortic Aneurysm and Aortic Dissection

Figure 2: Aorta and Bulging Vessel Wall (aneurysm)

Figure 3: Risk Factors of Abdominal Aortic Aneurysm

Figure 4: Non-contrast Axial (A, B) and Coronal (C) CT Images

Figure 5: Axial and Coronal CTA Images of the Abdomen

Figure 6: Axial (A), Coronal (B) and Sagittal (C) Images of the Chest and Abdomen

Figure 7: Axial (A) and Sagittal (B) Images From a CTA Study

Figure 8: Conventional catheter aortogram

Figure 9: Summary of the Pathogenesis of Abdominal Aortic Aneurysm

Figure 10: Diagnosis of Abdominal Aortic Aneurysm

Figure 11: Pathological mechanisms of AAA formation and therapeutic targets for pharmacological agents

Figure 12: Surgical techniques for abdominal aortic aneurysm

Figure 13: Open surgery: The aneurysm is replaced by an artificial vessel (graft)

Figure 14: Endovascular surgery with stent-graft

Figure 15: AAA treatment algorithm

Figure 16: Class II Device Approval Processes in the United States

Figure 17: Approval Processes in European Countries

Figure 18: Class II Device Approval Processes in Japan

Figure 19: Class III Device Approval Processes in Japan

Figure 20: Healthcare Reimbursement System in the US

Figure 21: AFX® Endovascular AAA System

Figure 22: ALTO™ Abdominal Stent Graft System

Figure 23: Company Revenue

Figure 24: INCRAFT® AAA Stent Graft System

Figure 25: Zenith® Fenestrated AAA Endovascular Graft Proximal Body Grafts

Figure 26: Zenith® Fenestrated AAA Endovascular Graft Distal Bifurcated Body Grafts

Figure 27: Zenith Alpha™ Abdominal Endovascular Graft Bifurcated Main Body Graft

Figure 28: Zenith® Spiral-Z® AAA Iliac Leg Graft

Figure 29: Zenith Renu® AAA Ancillary Graft Converter

Figure 30: Zenith Flex® AAA Endovascular Graft Bifurcated Main Body Graft

Figure 31: Gore® Excluder® Conformable AAA Endoprosthesis With Active Control System

Figure 32: TREO® Abdominal Stent Graft System

Figure 33: Anaconda™ Stent Graft System

Figure 34: Fenestrated Anaconda™

Figure 35: Treovance Stent Graft

Figure 36: Company Revenue

Figure 37: Endurant II AUI Stent Graft System

Figure 38: Company Revenue

Figure 39: R&D Expenses

Figure 40: Minos Abdominal Stent Graft System

Figure 41: Aegis™ Bifurcated Aortic Stent Graft System

Figure 42: Hercules™ Bifurcated Stent Graft System

Figure 43: Graft Linus®

Figure 44: Company Revenue

Figure 45: R&D Expenses

Figure 46: E-tegra

Figure 47: Company Revenue

Figure 48: R&D Expenses

Figure 49: Ankura™ AAA Stent Graft

Figure 50: AorfixTM

Figure 51: AlturaTM

Figure 52: Total Prevalent Population of AAA in 7MM (2019–2032)

Figure 53: Total Gender-specific Prevalent Population of AAA (2019–2032)

Figure 54: Total Size-Specific Prevalence of AAA (2019–2032)

Figure 55: Total Treatable Population of AAA (2019–2032)

Figure 56: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Figure 57: Total Diagnosed Prevalence of AAA (2019–2032)

Figure 58: Total Diagnosed Gender-Specific Prevalence of AAA (2019–2032)

Figure 59: Total Size-Specific Prevalence of AAA (2019–2032)

Figure 60: Total Treatable Population of AAA (2019–2032)

Figure 61: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Figure 62: Total Diagnosed Prevalence of AAA (2019–2032)

Figure 63: Total Diagnosed Gender-Specific Prevalence of AAA (2019–2032)

Figure 64: Total Size-Specific Prevalence of AAA (2019–2032)

Figure 65: Total Treatable Population of AAA (2019–2032)

Figure 66: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Figure 67: Total Diagnosed Prevalence of AAA (2019–2032)

Figure 68: Total Diagnosed Gender-Specific Prevalence of AAA (2019–2032)

Figure 69: Total Size-Specific Prevalence of AAA (2019–2032)

Figure 70: Total Treatable Population of AAA (2019–2032)

Figure 71: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Figure 72: Total Diagnosed Prevalence of AAA (2019–2032)

Figure 73: Total Diagnosed Gender-Specific Prevalence of AAA (2019–2032)

Figure 74: Total Size-Specific Prevalence of AAA (2019–2032)

Figure 75: Total Treatable Population of AAA (2019–2032)

Figure 76: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Figure 77: Total Diagnosed Prevalence of AAA (2019–2032)

Figure 78: Total Diagnosed Gender-Specific Prevalence of AAA (2019–2032)

Figure 79: Total Size-Specific Prevalence of AAA (2019–2032)

Figure 80: Total Treatable Population of AAA (2019–2032)

Figure 81: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Figure 82: Total Diagnosed Prevalence of AAA (2019–2032)

Figure 83: Total Diagnosed Gender-Specific Prevalence of AAA (2019–2032)

Figure 84: Total Size-Specific Prevalence of AAA (2019–2032)

Figure 85: Total Treatable Population of AAA (2019–2032)

Figure 86: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Figure 87: Total Diagnosed Prevalence of AAA (2019–2032)

Figure 88: Total Diagnosed Gender-Specific Prevalence of AAA (2019–2032)

Figure 89: Total Size-Specific Prevalence of AAA (2019–2032)

Figure 90: Total Treatable Population of AAA (2019–2032)

Figure 91: Total Treatable Population by Type of Treatment of AAA (2019–2032)

Figure 92: Total Market Size for AAA in 7MM in USD million (2019-2032)

Figure 93: Total Market Size for AAA by Pharmacological Therapies in 7MM in USD million (2019-2032)

Figure 94: Total Market Size for AAA in United States in USD million (2019-2032)

Figure 95: Total Market Size for AAA by Pharmacological Therapies in United States in USD million (2019-2032)

Figure 96: Total Market Size for AAA in Germany in USD million (2019-2032)

Figure 97: Total Market Size for AAA by Pharmacological Therapies in Germany in USD million (2019-2032)

Figure 98: Total Market Size for AAA in France in USD million (2019-2032)

Figure 99: Total Market Size for AAA by Pharmacological Therapies in France in USD million (2019-2032)

Figure 100: Total Market Size for AAA in Spain in USD million (2019-2032)

Figure 101: Total Market Size for AAA by Pharmacological Therapies in Spain in USD million (2019-2032)

Figure 102: Total Market Size for AAA in Italy in USD million (2019-2032)

Figure 103: Total Market Size for AAA by Pharmacological Therapies in Italy in USD million (2019-2032)

Figure 104: Total Market Size for AAA in United Kingdom in USD million (2019-2032)

Figure 105: Total Market Size for AAA by Pharmacological Therapies in United KIngdom in USD million (2019-2032)

Figure 106: Total Market Size for AAA in Japan in USD million (2019-2032)

Figure 107: Total Market Size for AAA by Pharmacological Therapies in Japan in USD million (2019-2032)

Endologix LLC
Cardinal Health
Cook Medical
W. L. Gore & Associates, Inc.
Medtronic
MicroPort Scientific Corporation
Artivion, Inc.
Lifetech Scientific (Shenzhen) Co., Ltd.
Lombard Medical
Endologix LLC
Latecba SA
Nectero Medical
Cardiatis, SA
Hangzhou Endonom Medtech Co., Ltd.

 

Forward to Friend

Need A Quote